Popular Articles
Ex-Blackstone pair team up again with David Blitzer, seal $400m debut 154 Partners fundraise...
154 Partners, a private equity firm launched by former Blackstone investors Isaac Harrouche and Mike Berlin, has reached a $400m hard cap close for its debut fund.
Neuberger acts as sole lead investor in CV for Tailwind Capital’s Axis Portable Air
Neuberger has acted as the sole lead investor in a single-asset continuation fund for Tailwind Capital portfolio business Axis Portable Air.
Saudi Arabia’s PIF plans to anchor King Street’s regional credit fund
Saudi Arabia's Public Investment Fund has made plans to anchor a private credit fund from King Street Capital targeting the country and the wider MENA region.
Latour Capital seals €400m close for oversubscribed debut small cap fund, less than a...
French private equity investor Latour Capital has sealed a €400m final close for its first small cap investment fund, less than a year after launch.
VC investor Eclipse brings AUM to $10bn with new double fund close
Silicon Valley-based venture capital investor Eclipse has picked up $1.3bn across its latest pair of funds, bringing its total assets under management to about $10bn.
Nova Infrastructure scores big fund size jump with $1.45bn Fund II final close
Mid-market investor Nova Infrastructure has hit a $1.45bn final close for its sophomore fund, beating its target by more than 30%.
Biotech investor Jeito Capital collects over €1bn for sophomore fund, almost double debut fund...
Biotech investor Jeito Capital has beaten its target for its sophomore fund to reach more than €1bn at final close.
The new vehicle is about...
Private equity ‘tertiaries’ pioneer Netley Capital expands deployable capital to $825m
Private equity ‘tertiaries’ pioneer Netley Capital has picked up more commitments to its strategy, bringing its deployable capital to about $825m.
ArcLight powers to $3.9bn final close for its biggest fund yet, 30% above target
Energy-focused private equity major ArcLight Capital Partners has soared past its Fund VIII target to reach a $3.9bn final close, marking its biggest vehicle to date.
Deal Roundup: EQT Life Sciences exits Tubulis to Gilead, Foresight scores 4x return selling...
EQT Life Sciences has exited its minority stake in Tubulis, a Germany-based clinical-stage biotech company developing next-generation antibody-drug conjugates.
